<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908228</url>
  </required_header>
  <id_info>
    <org_study_id>PS-CLL-008</org_study_id>
    <nct_id>NCT04908228</nct_id>
  </id_info>
  <brief_title>Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL</brief_title>
  <acronym>FIGHT</acronym>
  <official_title>Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paolo Ghia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 multicenter national interventional pharmacological study aimed at&#xD;
      determining the efficacy of a fixed duration treatment with ibrutinib and obinutuzumab in&#xD;
      terms of uMRD in the BM at the end of treatment (+30 Days follow-up).&#xD;
&#xD;
      Treatment with ibrutinib and obinutuzumab will be administered according to the following&#xD;
      schedule:&#xD;
&#xD;
      Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1&#xD;
      (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles&#xD;
      14-18 Day 1).&#xD;
&#xD;
      At the end of Cycle 24 all responding patients will discontinue ibrutinib and proceed with&#xD;
      follow-up. If disease relapse occurs at any time after discontinuing treatment, ibrutinib&#xD;
      therapy will be reintroduced at the standard dose of 420 mg QD and response to treatment&#xD;
      monitored over time. Patients with stable (SD) or progressive disease (PD) at the end of&#xD;
      Cycle 24, will continue ibrutinib as long as the treating physician deems they are benefiting&#xD;
      from treatment and will be followed up in the study for survival and response to subsequent&#xD;
      therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BM MRD &lt;10-4 at 30 days follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the rate of bone marrow minimal residual disease &lt;10-4 at +30 Days follow-up after ibrutinib and obinutuzumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate at 30 days follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate response to treatment after ibrutinib and obinutuzumab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Ibrutinib + obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib and obinutuzumab</intervention_name>
    <description>Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.</description>
    <arm_group_label>Ibrutinib + obinutuzumab</arm_group_label>
    <other_name>Imbruvica and Gazyvaro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)&#xD;
             that meets iwCLL diagnostic criteria&#xD;
&#xD;
          3. Previously untreated active disease requiring treatment per iwCLL criteria&#xD;
&#xD;
          4. ECOG PS 0 or 1&#xD;
&#xD;
          5. Measurable lymph node disease (&gt;1.5 cm longest diameter) by CT scan&#xD;
&#xD;
          6. Adequate hematologic function defined as:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &gt;750 cells/μL (750 cells/mm3 or 0.75 x 109/L)&#xD;
&#xD;
               2. Platelet count &gt;30,000/μL (30,000 cells/mm3 or 30 x 109/L)&#xD;
&#xD;
               3. Hemoglobin &gt;8.0 g/dL&#xD;
&#xD;
          7. Adequate hepatic and renal function defined as:&#xD;
&#xD;
               1. Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤3.0 x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               2. Estimated Creatinine Clearance (CrCl) ≥30 mL/min (Cockcroft- Gault)&#xD;
&#xD;
               3. Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  non-hepatic origin)&#xD;
&#xD;
          8. Prothrombin time (PT)/International normal ratio (INR) &lt;1.5 x ULN and PTT (activated&#xD;
             partial thromboplastin time [aPTT]) &lt;1.5 x ULN (unless abnormalities are unrelated to&#xD;
             coagulopathy or bleeding disorder).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any prior therapy (including but not limited to chemotherapy, targeted therapy,&#xD;
        immunomodulating therapy, radiotherapy, and/or monoclonal antibody) used for treatment of&#xD;
        CLL or SLL.&#xD;
&#xD;
        2. Patients carrying del(17p) and/or TP53 mutation as assessed by central laboratory.&#xD;
&#xD;
        3. History of other malignancies, except:&#xD;
&#xD;
          1. Malignancy treated with curative intent and with no known active disease present for&#xD;
             ≥3 before the first dose of study drug and felt to be at low risk for recurrence by&#xD;
             the treating physician&#xD;
&#xD;
          2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of&#xD;
             disease&#xD;
&#xD;
          3. Adequately treated carcinoma in situ without evidence of disease. 4. Known or&#xD;
             suspected history of Richter's transformation. 5. Known hypersensitivity to one or&#xD;
             more study drugs. 6. Known bleeding disorders (eg, von Willebrand's disease or&#xD;
             hemophilia). 7. History of stroke or intracranial hemorrhage within 6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
             8. Known history of human immunodeficiency virus (HIV) or active infection with&#xD;
             hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for&#xD;
             hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C&#xD;
             antibody must have a negative polymerase chain reaction (PCR) result before enrolment.&#xD;
             Those who are PCR positive will be excluded. 9. Unable to swallow capsules/tablets or&#xD;
             malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel, symptomatic inflammatory bowel disease or&#xD;
             ulcerative colitis, or partial or complete bowel obstruction.&#xD;
&#xD;
             10. Concomitant use of warfarin or other vitamin K antagonists. 11. Major surgery&#xD;
             within 4 weeks of first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paolo Ghia, MD, PhD</last_name>
    <phone>+39022643</phone>
    <phone_ext>4797</phone_ext>
    <email>ghia.paolo@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eloise Scarano, PhD</last_name>
    <phone>+39022643</phone>
    <phone_ext>3919</phone_ext>
    <email>scarano.eloise@hsr.it</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Paolo Ghia</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

